Efficient Bone Formation in a Swine Socket Lift Model Using Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 Adsorbed in β-Tricalcium Phosphate
Authors:
- Wataru SonoyamaWSWataru Sonoyama
- Katushi YamamotoKYKatushi Yamamoto
- Yasutaka OidaYOYasutaka Oida
- Kentaro AkiyamaKAKentaro Akiyama
- Shigehiko ShinkawaSSShigehiko Shinkawa
- Ryu NakajimaRNRyu Nakajima
- Hai T. PhamHai T. Pham
- Emilio S. HaraEHEmilio S. Hara
- Takuo KubokiTKTakuo Kuboki
- 1 January 2014
- journal article
- Published by S. Karger AG in Cells Tissues Organs
- Vol. 199 (4) , 249-255
Abstract
Several preclinical studies have shown that Escherichia coli-derived bone morphogenetic protein-2 (E-BMP-2) is as effective as mammalian cell-derived bone morphogenetic protein-2 (C-BMP-2) in the treatment of bone defects. However, further investigation of the effectiveness and determination of the optimal dosage of E-BMP-2 in large animals are still necessary before its full application in humans. This study investigated the efficiency of different concentrations of E-BMP-2 adsorbed in β-TCP for bone augmentation and osseointegration of immediate dental implants in a swine socket lift model. Following exposure of the maxillary sinus lateral wall, a 3.4-mm (diameter) cavity was drilled and filled with 0.1 g of β-TCP containing different doses of E-BMP-2 (0, 10, 30, or 100 μg/site) to lift the Schneiderian membrane. A dental implant was then immediately inserted. Bone-to-implant contact (BIC) and bone density (BD) examined via histological analysis were used as parameters to assess E-BMP-2 efficiency in bone formation. The implant stability quotient (ISQ) was measured using Osstell to determine the effect of E-BMP-2/β-TCP on implant stability. After 8 weeks, the groups that received 30 and 100 μg of E-BMP-2 showed substantial new bone formation in the elevated space, while no bone formation was observed with β-TCP alone. Accordingly, BIC and BD presented a dose-dependent response to increasing doses of E-BMP-2. However, there was no increase in implant stability with E-BMP-2 treatment. In conclusion, the E-BMP-2/β-TCP combination was efficient in bone formation and osseointegration of dental implants in a socket lift model in mini-pigs.Keywords
This publication has 17 references indexed in Scilit:
- Alveolar ridge augmentation using anodized implants coated with Escherichia coli–derived recombinant human bone morphogenetic protein 2Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011
- Sinus augmentation using absorbable collagen sponge loaded with Escherichia coli‐expressed recombinant human bone morphogenetic protein 2 in a standardized rabbit sinus model: a radiographic and histologic analysisClinical Oral Implants Research, 2011
- Orthodontic Tooth Movement in Alveolar Cleft Repaired with a Tissue Engineering Bone: An Experimental Study in DogsTissue Engineering Part A, 2011
- Influence of rhBMP-2 on bone formation and osseointegration in different implant systems after sinus-floor elevation. An in vivo study on sheepJournal of Cranio-Maxillofacial Surgery, 2010
- Early Implant Survival in Posterior Maxilla With or Without β-Tricalcium Phosphate Sinus Floor GraftJournal of Oral and Maxillofacial Surgery, 2010
- Factors influencing resonance frequency analysis assessed by Osstell™mentor during implant tissue integration: II. Implant surface modifications and implant diameterClinical Oral Implants Research, 2010
- Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processingJournal of Bone and Mineral Metabolism, 2009
- Histological and histomorphometrical comparative study of the degradation and osteoconductive characteristics of α‐ and β‐tricalcium phosphate in block graftsJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2007
- Bone allograftsThe Journal of Bone and Joint Surgery. British volume, 2007
- The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applicationsExpert Opinion on Biological Therapy, 2004